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Abstract
INTRODUCTION: Ovarian cancer is the leading cause of mortality from gynecological malignancy despite advance-
ments in novel therapeutics. We have recently demonstrated that the transcriptional co-repressor C-terminal binding
protein 2 (CtBP2) is overexpressed in epithelial ovarian carcinoma.MATERIALS ANDMETHODS: Reverse-transcribed
cDNA from CtBP2 wild-type and knockdown ovarian cancer cell lines was hybridized to Affymetrix Gene 1.0 STmicro-
arrays, and differentially expressed genes were studied. Immunohistochemical analysis of CtBP2 and BRCA1 stain-
ing of ovarian tissues was performed. Chromatin immunoprecipitation (ChIP) and luciferase assays were carried out.
The effect of the drugs 4-methylthio-2-oxobutyric acid (MTOB) and poly(ADP-ribose) polymerase (PARP) inhibitor
Olaparib on CtBP2 wild-type and knockdown cell lines was examined using methylthiazol tetrazolium assays and
an xCELLigence System. RESULTS: Eighty-five genes involved in DNA repair, mitotic checkpoint, nucleosome assem-
bly, and the BRCA1 network were differentially regulated by CtBP2 expression. ChIP and luciferase reporter assays
using a BRCA1 promoter–regulated luciferase construct indicated that the CtBP2 complex binds the BRCA1 promoter
and represses BRCA1 transcription. Immunohistochemistry illustrated a significant inverse CtBP2 and BRCA1 expres-
sion in a panel of malignant ovarian tumor tissues. The CtBP2 inhibitor MTOB suppressed ovarian cancer cell survival
in a CtBP2-dependent manner. Ovarian cancer cells with CtBP2 knockdown did not display increased sensitivity to
the PARP inhibitor Olaparib. CONCLUSION: CtBP2 is an ovarian cancer oncogene that may play a significant role
in epigenetically silencing BRCA1 function in sporadic epithelial ovarian cancer. CtBP2-specific inhibitors, such as
MTOB, may be effective adjunct therapies in the management of patients with CtBP2-positive ovarian carcinoma.
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Introduction
Ovarian carcinoma has the highest fatality-to-case ratio of all gyne-
cological malignancies. Thus, although ovarian cancer is the second
most common gynecological malignancy, it accounts for the highest
mortality rate among gynecological cancers. The majority of patients
with epithelial serous cancer, the most common epithelial ovarian
malignancy, present with metastatic disease, which has a 5-year sur-
vival rate of less than 25% and a 10-year survival rate approaching
zero [1]. This alarming death rate is not only attributed to the ad-
vanced stage of disease at diagnosis but also to the lack of effective
therapy for ovarian carcinoma. Therefore, what is urgently needed to
impact survival in ovarian carcinoma are advances in development
of disease-specific, targeted therapy. It is thus imperative to under-
stand the biology of ovarian cancer and define the molecular events
associated with malignant transformation and carcinogenesis.
C-terminal binding protein 2 (CtBP2) is a novel ovarian cancer
tumor antigen that is overexpressed in most epithelial ovarian carci-
noma [2,3]. Early studies suggested that CtBP2 may be a transcrip-
tional co-repressor; however, recent data suggest that it may play a
dual role in genetic transcription as it can act as both a transcriptional
repressor and activator [4,5]. CtBP2 affects epithelial gene regulation
and programmed cell death [6,7]. Survival analyses indicate worst sur-
vival in patients with positive CtBP2 expression [8]. Bergman and
Blaydes demonstrated that CtBP proteins promote cell survival by
suppressing the expression of several proapoptotic genes, thus acting
as apoptotic transcriptional regulators [9]. Furthermore, CtBPs pro-
mote cell survival through the maintenance of mitotic fidelity [10].
Loss of CtBP expression suppresses cell proliferation through a combina-
tion of apoptosis, reduction in cell cycle progression, and aberrations
in transit through mitosis [10].
Importantly, CtBP2 forms transcriptional complexes with more than
30 different transcriptional factors [2]. The CtBP2 complex regulates
gene expression through epigenetic mechanisms. Epigenetic deregula-
tions play a significant role in human cancer development. There are
different mechanisms of epigenetic changes including acetylation and
methylation of nucleosomal histones. CtBP2 protein is believed to
be involved in chromatin remodeling and regulation of transcription
programs in cancer cells through histone modification [4,11].
We have previously identified overexpression of CtBP2 in ovarian
cancer and its function in regulating cell growth and chemoresponse
[8,12]. Here, we designed a study aimed at examining the role of
CtBP2 in epithelial ovarian carcinogenesis. Our objectives are to iden-
tify the gene expression profiles of ovarian cancer cells with knockdown
of CtBP2, to highlight cellular pathways regulated or altered by CtBP2
in ovarian cancer, and to identify potential targeted therapy for ovarian
carcinoma with elevated CtBP2 levels.
Materials and Methods
Establishment of Ovarian Cancer Cell Lines with
Knockdown or Ectopic Expression of CtBP2
MCAS and SKOV3 ovarian cancer cells (1 × 105) were infected
with 5 × 105 Mission lentiviral CtBP2-targeting shRNA and nontarget
control shRNA transduction particles (Sigma-Aldrich, St Louis,MO) in
the presence of 8 μg/ml hexadimethrine bromide (Sigma-Aldrich)
and incubated overnight at 37°C and 5% CO2. Puromycin (2 μg/ml)
was added to the complete medium on the third day and changed
every 3 days for 2 weeks. MCAS shRNA control cell lines were trans-
fected with full-length CtBP2 cDNA expression construct or empty
vector (OriGene Technologies, Rockville, MD) using Lipofectamine
2000 transfection reagent (Invitrogen Corp, Carlsbad, CA). The trans-
fected cells were selected using complete medium containing 500 μg/ml
G418 (Invitrogen Corp). The cell lines were maintained in a 1:1 mix-
ture of 199 medium and MCDB105 medium (Sigma, St Louis, MO)
supplemented with 10% fetal calf serum (Invitrogen Corp). Knockdown
of CtBP2 expression and stable clones with overexpression of CtBP2
were confirmed by Western blot analysis.
RNA Extraction and Gene Expression Profiling
RNA was extracted from SKOV3 and MCAS shRNA control and
CtBP2 knockdown cell lines using TRIzol reagent (Invitrogen Corp).
The quality and quantity of the RNA were tested using spectro-
photometric analysis and Bioanalyzer (Agilent Technologies, Santa
Clara, CA). RNA (1 μg) from each sample was used for gene expres-
sion profiling. cRNA was synthesized in a T7 polymerase–catalyzed
reaction containing unmodified ribonucleoside triphosphates. cDNA
was synthesized from the cRNA template using random primers and
deoxyuridine triphosphate (dUTP), deoxythymidine triphosphate
(dTTP), deoxyadenosine triphosphate (dATP), deoxycytidine triphos-
phate (dCTP), and deoxyguanosine triphosphate (dGTP). Uracil
DNA glycosylase and apurinic/apyrimidinic endonuclease I were used
to fragment the cDNA at uracil-containing positions. The fragmented
cDNA was end-labeled with a biotinylated nucleotide analog. The
fragmented cDNA was added to a hybridization solution containing
biotinylated control oligonucleotides and hybridized to the Human
Gene 1.0 ST GeneChip microarrays overnight at 45°C. Unbound
cDNAwas then washed out using fluidics instrument and the remaining
bound cDNA was fluorescently labeled using phycoerythrin-conjugated
streptavidin. Additional fluorescents were added using biotinylated
anti-streptavidin antibody and additional phycoerythrin-conjugated
streptavidin. Each cDNA bound at its complementary oligonucleotide
was excited using a confocal laser scanner and the positions and in-
tensities of the fluorescent emissions were captured. The data were
transferred to a file system ready for data analysis.
Gene Expression Profiling Data Analysis
Expression data in CEL file format were imported into R and Bio-
conductor software. All Affymetrix control genes were removed and the
remaining Affymetrix probe clusters were imported into the Affymetrix
Power Tools software (APT package). The data were normalized by
robust multichip average (RMA) preprocessing followed by “per chip”
normalization, i.e., data were normalized to the median of all probe sets
on each chip, and lastly by “per gene” normalization, i.e., normalized to
the median expression of each probe set across all samples. An analysis
of variance with a Benjamini and Hochberg multiple testing correction
of P < .05 was performed on the filtered data set to find differences
between the wild-type shRNA control cell lines and the CtBP2 knock-
down cell lines. To further look for differences between the various
combinations of subtypes, t tests were performed with a Benjamini
and Hochberg multiple testing correction cutoff of P < .05. Differen-
tially expressed genes between the wild-type cell lines and the CtBP2
knockdown cell lines were imported into the Ingenuity Systems Path-
way Analysis (www.ingenuity.com) and GeneGo MetaCore Pathway
Analysis and were annotated with protein-protein interactions from
the intact repository to identify differentially expressed networks.
Twenty-seven differentially expressed genes were selected for validation
studies using quantitative real-time reverse transcription–polymerase
chain reaction (qRT-PCR).
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Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed on
SKOV3 and MCAS ovarian cancer cells. The cells were grown in 199
and MCDB105 media (Sigma-Aldrich) supplemented with 10% fetal
calf serum (Invitrogen Corp) and incubated at 37°C in a humidified
5% CO2 incubator. Approximately 5 × 10
7 cells in suspension were
cross-linked with 1% formaldehyde solution for 10 minutes at 37°C.
The reaction was stopped with cold 1× phosphate-buffered saline (PBS)
plus BSA. The cells were then washed with cold 1× PBS and then
scraped into PBS plus complete protease inhibitors (Roche, Basel,
Switzerland). They were lysed with lysis buffer [50 mM Tris-HCl
(pH 8.0), 10 mM EDTA, and 1% sodium dodecyl sulfate (SDS)] sup-
plemented with Complete protease inhibitors (Roche) for 10 minutes.
The cells were then sonicated on a Vibra-Cell VCX 130 (Sonics,
Newtown, CT) using a 3-mm tip with four 30-second pulses
at 12% amplitude. Fractions of the clarified lysates were stored at
−20°C as input samples. The remainder of the lysates were diluted with
10 volumes of ChIP dilution buffer [20 mM Tris-HCl (pH 8.0),
150 mM NaCl, 2 mM EDTA, and 1% Triton X-100] and incubated
overnight at 4°C with various selected antibodies prebound to Dynal
magnetic beads (Invitrogen Corp). The anti-CtBP2 antibody was
from BD Biosciences (San Jose, CA). The anti–acetyl histone H3
(Lys9), anti–acetyl histone H3 (Lys14), and ChIPAb+ dimethyl histone
H3 (Lys9) antibodies were from EMD Millipore (Billerica, MA). The
anti–polymerase II (Pol II) (N-20)X antibody was from Santa Cruz
Biotechnology (Dallas, TX). The DNA-protein bead complexes were
washed with RIPA buffer [50 mM Hepes (pH 7.6), 0.7% sodium
deoxycholate, 1% NP-40, and 0.5 M lithium chloride] six times and
then twice with TE buffer [10 mM Tris-HCl (pH 8.0) and 1 mM
EDTA]. The DNA-protein cross-links were reversed in the ChIP
and input samples by adding 100 μl of reverse buffer (1% SDS and
0.1 MNaHCO3) and heating to 65°C for 6 hours. The ChIP-enriched
DNA and input chromatin DNA were purified using QIAquick PCR
Purification Kit (Qiagen, Valencia, CA) according to the manufac-
turer’s protocol and stored at −20°C for further studies.
qRT-PCR and Quantitative Real-Time PCR
qRT-PCRs were performed to validate differentially expressed genes
identified by gene expression profiling. Primer sets corresponding to
the genes of interest were designed using the Primer Express Software
(Applied Biosystems, Foster City, CA; Table W1). Quantitative real-
time PCRs (qPCRs) were performed to quantify the gene-specific
chromatin DNA obtained following ChIP assays and the corre-
sponding input samples. Primer sequences corresponding to promoter
sequences for BRCA1 and CDX1 ChIP qPCR were conducted as de-
scribed by Di et al. and Joo et al. [13,14]. Twenty-microliter mixtures
were prepared using the following components for each reaction: 10 μl
of SYBER Green PCR Master Mix (Applied Biosystems), 1.6 μl
of 5 μM forward and reverse primers, 1 μl of DNA template, and
7.4 μl of double distilled H2O. The mixtures were placed in a 96-well
plate (BrandTech Scientific, Essex, CT), and the reaction was carried
out in a 7300 Real-Time PCR System (Applied Biosystems). A cycle
threshold (CT) value was recorded for each sample using a 7300 SDS
software (Applied Biosystems). For qRT-PCR, the expression of each
gene in each sample relative to the control was calculated using the
2−ΔΔCT method to relate the CT values of gene expression to the CT
values for the housekeeping gene cyclophilin A. ChIP qPCR data were
normalized against qPCR data of the input DNA. All qPCR reactions
were repeated at least twice for mean values and SDs. Significance of
differences in CT values of the treatment group was determined using a
two-tailed t test on testing whether the mean is different from the value
of 1.0, which was set for controls. A difference was deemed significant
when it reached the 5% level, i.e., P ≤ .05.
Immunohistochemistry for BRCA1 and CtBP2 Expression
Correlation Analysis
Immunohistochemistry (IHC) was performed on a panel of
48 archived formalin-fixed, paraffin-embedded malignant ovarian carci-
noma tissues. The corresponding blocks were sectioned at a thickness of
7 μm, mounted on SuperFrost Plus Microscope Slides (Fisher Scientific,
Pittsburgh, PA), and dried at 50°C for 24 hours. Deparaffinization was
achieved using xylene followed by rehydration with a descending series
of ethanol solutions. Antigen retrieval was performed using antigen-
unmasking solution (Vector Laboratories, Burlingame, CA) in a pressure
cooker. Endogenous peroxidases were then blocked using 0.3% H2O2
in methanol for 15 minutes. Following a 30-minute blocking with the
corresponding normal serum, sections were incubated with primary
antibodies at 4°C overnight. The two primary antibodies used were
CtBP2mouse IgG1 antibody (BDBiosciences) and BRCA1monoclonal
mouse antibody (EMD Millipore). The reaction was visualized using
VECTASTAIN Elite ABC Kit with DAB chromogen as a substrate
(Vector Laboratories). Sections were lightly counterstained with hema-
toxylin and mounted. Immunohistochemical results were evaluated
blindly by two trained investigators. Staining was graded semiquantita-
tively and the final histologic score was obtained by multiplying the pro-
portion of the stained epithelial area (from 0 for absence to 3 for more
than 95% of the total epithelial area) with the intensity of the stain (from
0 for no stain to 3 for highly intense stain). Pearson correlation analysis
was performed to evaluate the correlation between BRCA1 and CtBP2
expression. A ceiling effect was observed for CtBP2 scores, and therefore,
cases with highest CtBP2 scores of 9 were excluded in the analyses.
Luciferase Assay
Because our SKOV3 cells were integrated with an exogenous
luciferase reporter gene, only the MCAS cell lines were used in this
assay. The BRCA1 promoter–firefly luciferase reporter plasmid has
been described before [15]. MCAS cells with variable CtBP2 expres-
sion were co-transfected with this plasmid and a Renilla luciferase–
encoding pRL-CMV plasmid (Promega, Madison, WI) as an internal
control, using Lipofectamine 2000 reagent (Invitrogen Corp). Follow-
ing a 48-hour incubation period, the cells were washed with 1× PBS
and 1× passive lysis buffer (Promega) was added. Cells were lysed for
15 minutes at room temperature. The lysates were transferred to a
microtube and were subjected to a single freeze-thaw cycle. The cell
lysates were then centrifuged at 12,000g for 15 seconds and the super-
natant was used for the assay. Firefly and Renilla luciferase activities
of cell lysates were measured using the Dual Luciferase Assay Sys-
tem (Promega) in a Turner TD-20/20 luminometer (Turner Designs,
Sunnyvale, CA) according to the manufacturer’s instruction. The
relative firefly luciferase activity was normalized to Renilla luciferase
activity for each cell line. The results were repeated three times and
reported as means ± SEs. Significance of differences was determined
using two-tailed t test. A difference was deemed significant when it
reached the 5% level, i.e., P ≤ .05.
In Vitro Cell Survival Assessment Following Drug Treatment
SKOV3 and MCAS ovarian cancer cells with various levels of CtBP2
expression were seeded in triplicates in 96-well plates and treated with
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the poly(ADP-ribose) polymerase (PARP) inhibitor Olaparib (AZD221;
Selleck, Houston, TX) in serial dilutions. After a 48-hour incuba-
tion period, 20 μl of 5 mg/ml methylthiazol tetrazolium solution
was added to each well and incubated for 4 hours. The medium
was removed and 100 μl of combined solubilization solutions (half
of 10% SDS in 0.01 N HCl and half of 0.1 N HCl in 2-propanol)
was added to each well. The plates were shaken to dissolve the blue
formazan crystals and then read using a microplate reader at an
absorbance of 562 nm. Ovarian cancer cells were also treated with
serial dilutions of 4-methylthio-2-oxobutyric acid (MTOB; Sigma-
Aldrich) and viability measured by methylthiazol tetrazolium assay.
In addition, real-time cell viability was also determined for the MTOB
treatments using an xCELLigence System (Roche Applied Science,
Indianapolis, IN), which measured electrical impedance across inter-
digitated gold microelectrodes on the bottom of a tissue culture plate.
The culture plate was assembled on the RTCA DP analyzer and data
were gathered at 5-minute intervals for 10 hours at 37°C in 5% CO2
chamber. The data obtained were analyzed using the RTCA software
(Roche Applied Science).
Results
Establishment of Ovarian Cancer Cell Lines with Differential
Expression of CtBP2
SKOV3 and MCAS ovarian cancer cell lines were successfully trans-
duced with lentivirus containing control shRNA or CtBP2 shRNA
constructs yielding CtBP2 wild-type cell lines (SKOV3-CON and
MCAS-CON) and CtBP2 knockdown cell lines (SKOV3-Sh2,
SKOV-Sh3, andMCAS-Sh2; MCAS-Sh3 was lost during maintenance
of cell lines and was reestablished only after the gene expression
profiling experiment), respectively. We have also established MCAS
ovarian cancer cell lines that stably harbored an exogenous copy of
CtBP2 expression construct.Western blot analysis (FigureW1) showed
that there was a specific reduction of CtBP2 expression, not the more
ubiquitously expressing CtBP1 expression in the knockdown cell
lines. The cell lines with exogenous copy of CtBP2 expression con-
struct showed almost no increase of CtBP2 protein levels, even though
qRT-PCR confirmed overexpression of the transcripts (data not shown).
There has been report suggesting a post-transcriptional mechanism to
maintain a threshold of CtBP2 protein level [16].
Gene Expression Profiling to Identify Genes Regulated
by CtBP2
Normalized gene expression data over 30,000 genes in each of
the SKOV3-CON, SKOV3-Sh2, SKOV3-Sh3, MCAS-CON,
and MCAS-Sh2 cell lines were analyzed to yield an 85-gene expres-
sion signature (Figure W2), largely involved in mitotic checkpoint,
nucleosome assembly, and DNA repair, to be differentially expressed
between the CtBP2 wild-type and knockdown cell lines (Table W2).
Pathway analyses using both GeneGo MetaCore and Ingenuity Path-
way Analysis programs highlighted key functional networks regu-
lated by CtBP2 including cell cycle regulation, DNA replication and
repair, and chromatin assembly (Table W3). In particular, Inge-
nuity analysis highlighted an enrichment of differentially expressed
genes including BRCA1 in a DNA damage response pathway (Fig-
ure 1A). Selected differentially expressed genes were validated using
qRT-PCR on cDNA from CtBP2 wild-type and knockdown cell
lines (Figure W3).
CtBP2 Regulates BRCA1 Expression in Ovarian Cancer Cells
We were interested in the potential control of CtBP2 on BRCA1
expression in ovarian cancer cells. Western blot analysis showed that
the CtBP2 knockdown cell lines had significantly increased levels of
BRCA1 protein, whereas in ovarian cancer cells that stably harbored
an exogenous copy of CtBP2 expression construct, there was signif-
icant repression of the BRCA1 expression (Figure 1B). To explore
whether CtBP2 binds to BRCA1 promoter and regulates BRCA1
transcription in ovarian cancer cells, ChIP analysis was performed on
the CtBP2 wild-type and knockdown cell lines using an anti-CtBP2
monoclonal antibody. qPCR on the ChIP DNA products using a
BRCA1 promoter primer set showed significant reduction of CtBP2
binding to BRCA1 promoter in the CtBP2 knockdown cell lines
compared to the CtBP2 wild-type cell lines (Figure 2A). As CtBP
co-repressor complex was known to regulate gene expression through
histone modifications at the bound sites, we evaluated the histone
activation status at the BRCA1 promoter in the ovarian cancer cell
lines by employing the anti–acetyl histone H3 (Lys9) and anti–acetyl
histone H3 (Lys14) antibodies in ChIP experiments on CtBP2 wild-
type and knockdown cell lines. The results indicated that the knock-
down cell lines had increased histone activation–associated acetylation
at the BRCA1 promoter (Figure 2, B and C). To confirm the results,
anti–dimethyl histone H3 antibody was used in the ChIP assay and
Figure 1. Gene expression profiling to identify differentially ex-
pressed gene signatures in the CtBP2 knockdown cell lines. (A) A
novel BRCA1 DNA damage response pathway identified by Ingenu-
ity Pathway Analysis program. (B) Western blot analysis to show
that BRCA1 protein expression in the MCAS cells corresponds to
cellular CtBP2 expression. β-Actin was used as a loading control.
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the results showed that the knockdown cells had reduced level of
suppression-associated histone methylation compared to the CtBP2
wild-type cell lines (Figure 2D). Lastly, use of an RNA Pol II–specific
antibody in the ChIP assay also showed increased association of Pol II
with the BRCA1 promoter in the knockdown cell lines (Figure 2E).
To evaluate the BRCA1 promoter activity in the cancer cell lines,
transient transfection of a firefly luciferase cDNA plasmid under the
control of the BRCA1 promoter was performed with MCAS cell
lines with, respectively, CtBP2 wild-type, CtBP2 knockdown, and
expression of an exogenous CtBP2 expression construct. Results
of the luciferase assays demonstrated that BRCA1 promoter ac-
tivity was inversely related to the expression level of CtBP2 in the
ovarian cancer cell lines and corroborated Western blot analysis re-
sults (Figure 2F ). Hence, all the results indicate that cellular BRCA1
expression is negatively correlated with CtBP2 expression in ovarian
cancer cells.
Di et al. have reported that estrogen induction resulted in CtBP
loss from the BRCA1 promoter and increased BRCA1 transcription
[13]. We investigated if estrogen stimulation could affect BRCA1 ex-
pression in ovarian cancer cells. Western blot analysis of cell lysates
after estrogen stimulation did not result in changes of BRCA1 expres-
sion. Probing of the membrane for estrogen receptor expression showed
that there was little to no expression of estrogen receptor in our panel
of ovarian cancer cell lines (Figure W4).
Figure 2. CtBP2 binds to BRCA1 promoter and epigenetically represses BRCA1 expression. (A) ChIP assay using anti-CtBP2 antibody.
(B) ChIP assay using anti–acetyl histone H3K9 antibody. (C) ChIP assay using anti–acetyl histone H3K14 antibody. (D) ChIP assay using
anti–dimethyl histone H3 antibody. (E) ChIP assay using anti–RNA Pol II antibody. All the ChIP data are shown relative to the controls
(defined as 1). (F) Luciferase reporter assay to determine the BRCA1 promoter activity. Results shown are averages of both MCAS and
SKOV3 cancer cell lines and all significant values are relative to control. Significance of differences was determined using two-tailed
t test. *P < .01; **P < .05.
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Clinical Ovarian Tumors Showed Inverse Relationship
between CtBP2 and BRCA1 Expression
To evaluate the clinical relevance of CtBP2 control on BRCA1
expression, we stained a panel of 48 malignant ovarian tumors for
CtBP2 and BRCA1 proteins. Any tumor cases with known BRCA1
mutations were excluded from this study. Forty-two malignant
ovarian tumors stained strongly positive (score of 5 or above) for
CtBP2, with 33 of them showing correspondingly weak or no
BRCA1 signals (0 to 4). There were five samples that stained rela-
tively weak (below 4) for CtBP2; four of them had BRCA1 scores
higher than 5. Statistical analysis of the CtBP2 and BRCA1 staining
in the clinical samples showed a significant Pearson correlation co-
efficient of −0.495 (r2 = 0.245, P = .005). Representative IHC
samples with this inverse expression relationship and a scatterplot
of the data are shown in Figure 3. Hence, taken together, the in vivo
data are consistent with the in vitro findings and support the notion
of regulation of BRCA1 expression by CtBP2 co-repressor complex
in ovarian cancer cells.
Ovarian Cancer Cell Lines with Changes of CtBP2 Expression
Showed Differential Response to CtBP2 Inhibitor but
Similar Response to the PARP Inhibitor Olaparib
As patients with BRCA mutations showed positive response to
DNA-damaging agents such as PARP inhibitors [17–19], MCAS cell
lines with CtBP2 wild-type, knockdown, and an exogenous CtBP2
expression construct were treated with serial dilutions of the PARP
inhibitor Olaparib. Cell survival at various Olaparib concentrations
was similar among all the cell lines irrespective of the CtBP2 expression
status (Figure 4A). Importantly, as CtBP2 is overexpressed in most of
the malignant ovarian tumors and regulates BRCA1 function, CtBP2
may serve as an important target for chemotherapeutic treatment of
ovarian cancer. As a pilot test to this hypothesis, we have treated the
same cancer cell lines with MTOB, which inhibits CtBP2’s dehydro-
genase activity at high concentrations [20]. As shown in Figure 4B,
even though MTOB exhibited modest cytotoxicity at low doses, the
survival of cancer cell lines to MTOB was inversely related to cellular
CtBP2 level at higher doses. We have also measured the MTOB
Figure 3. IHC to investigate the relationship between CtBP2 and BRCA1 protein expression in clinical ovarian tumors. (A) Representative
images of malignant ovarian carcinomas that show negative association of CtBP2 and BRCA1 staining. Scale bar represents 50 μm.
(B) A scatterplot to show the negative relationship between CtBP2 and BRCA1 protein staining.
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effects using the Roche xCELLigence System and similar results were
obtained (Figure W5A). To evaluate if cellular BRCA1 level changes
with the MTOB treatment, Western blot analysis of the cell lysates
after MTOB treatments was performed. The results showed general
down-regulation of BRCA1 levels with increasing doses of MTOB.
The CtBP2-overexpressing line lost almost all the BRCA1 expression
beginning with 1 mM MTOB, whereas cancer cell lines with CtBP2
knockdown maintained higher levels of BRCA1 (Figure W5B).
Discussion
In this study, ovarian cancer cell lines with knockdown of CtBP2 ex-
pression were established and gene expression profiling was performed.
Gene signatures for the knockdown cell lines were identified and the
various gene expression levels were compared to control cell lines with
wild-type CtBP2 expression. This allowed for identification of critical
pathways altered by suppressed CtBP2 expression in ovarian cancer.
Cell cycle genes and DNA recombination and repair genes, including
BRCA1 and Fanconi anemia, complementation group D2 (FANCD2)
gene, were upregulated in CtBP2 knockdown cell lines compared to
wild-type, control cell lines. This suggested that the CtBP2 co-repressor
complex regulates BRCA1 expression in ovarian cancer cells.
The breast and ovarian tumor suppressor BRCA1 is a well-recognized
biologic agent in ovarian tumorigenesis. BRCA1 has important func-
tions in cell cycle checkpoint control and DNA repair [21]. Mutations
in the BRCA1 gene can cause defective double-stranded DNA repair
through homologous recombination [21]. Germ-line mutations in the
BRCA1 gene predispose females to ovarian cancer and account for ap-
proximately 8% of invasive epithelial ovarian carcinoma in the general
population [22–24]. Notably, the BRCAness concept is an interesting
trait found in many human cancers [25] including ovarian cancer
[26,27]. Sporadic tumors exhibiting BRCAness behavior may exhibit
deregulation of molecular pathways similar to those occurring in tumors
with BRCA gene mutations. The inactivation of BRCA1 in sporadic
ovarian cancer may occur through a number of epigenetic mechanisms
including aberrant methylation of the BRCA1 promoter [28]. Cytosine
methylation of the CpG islands in the BRCA1 promoter leads to
Figure 4. Sensitivity of ovarian cancer cell lines with changes of CtBP2 expression to (A) PARP inhibitor Olaparib and (B) CtBP2 inhibitor
MTOB. *P < .05 relative to the control cell lines.
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repressed expression and function of the BRCA1 protein. Ultimately, this
leads to an ovarian cancer clinical presentation that appears similar to that
encountered in BRCA1 gene mutation carriers. Importantly, the most
recent report of The Cancer Genome Atlas research network indicates
that 8.5% of high-grade serous ovarian tumors have BRCA1 germ-line
mutations, 3% somatic BRCA1 mutations, and 11.5% epigenetic
BRCA1 silencing due to DNA hypermethylation [29].
Our data show that knockdown of CtBP2 in ovarian cancer cells re-
verses the suppression of BRCA1 expression. ChIP analyses using anti-
bodies targeting CtBP2, RNA Pol II, and histone activation markers
indicate that cell lines with CtBP2 knockdown have reduced binding
of the CtBP2 co-repressor complex and increased activity of the BRCA1
promoter compared to ovarian cancer cells with wild-type CtBP2 levels.
These findings are further affirmed by the results of the luciferase assays
using a BRCA1 promoter–luciferase reporter construct. Hence, our
data demonstrate that histone modification of the BRCA1 promoter
by the CtBP2 co-repressor complex may represent an important mecha-
nism in BRCA1 silencing in ovarian cancer cells. Moreover, IHC anal-
ysis of BRCA1 and CtBP2 expression in malignant ovarian tumor
tissues confirms the inverse association between BRCA1 and CtBP2 ex-
pression in clinical specimens and the clinical relevance of CtBP2 func-
tion. Di et al. showed that a “metabolic switch” by estrogen induction
drove CtBP loss from the BRCA1 promoter and increased BRCA1 tran-
scription, suggesting a molecular link between caloric intake and tumor
suppressor expression in mammary cells [13]. To this end, we propose
that this metabolic switch is disrupted in ovarian cancer, as we did not
find changes of BRCA1 in response to estrogen stimulation (FigureW4).
This lack of metabolic switchmight be due to little or absence of estrogen
receptor expression in the ovarian cancer cell lines.
The relation between CtBP proteins and chemoresistance in human
cancers has been previously described [2,16]. Furthermore, ovarian
cancer cells with BRCA1 gene mutations have increased sensitivity to
PARP inhibitors [17–19]. Our results indicate that ovarian cancer
cells with differential CtBP2 expression and thus differential BRCA1
protein expression did not display a differential response to the PARP
inhibitor Olaparib (Figure 4A). The most recent data of The Cancer
Genome Atlas indicate that ovarian cancer patients with epigenetically
silenced BRCA1 exhibit treatment response and survival that is simi-
lar to patients with wild-type BRCA status and are worse than patients
with BRCA1 gene mutations [29]. As such, tumors with epigenetic
BRCA1 silencing appear to be phenotypically different from tumors
with BRCA1 gene mutations.
Our group has previously demonstrated that CtBP2 is overexpressed
in ovarian carcinoma and down-regulation of CtBP2 impairs tumor
growth and increases drug sensitivity [8,12]. Hence, targeting CtBP2
may have therapeutic implications in ovarian carcinoma. Straza et al.
investigated the effect of the CtBP dehydrogenase inhibitor MTOB
at high concentrations on human cancers [20]. This chemical was
found to be cytotoxic to cancer cells and induced apoptosis in a p53-
independent manner [20]. We tested the effect of MTOB treatment
on ovarian cancer cell lines with differential CtBP2 expression. Indeed,
MTOB suppressed cell survival in cell lines with CtBP2 overexpression
compared to wild-type and CtBP2 knockdown cell lines. These re-
sults suggest that CtBP2 inhibition may provide a suitable therapeutic
index for cancer therapy. Furthermore, CtBP2 inhibitors such asMTOB
may represent effective targeted therapeutics for ovarian cancers with
elevated CtBP2 levels. It is intriguing that BRCA1 proteins in general
decreased with increasing doses of MTOB (Figure W5B). We hypothe-
size that the diminished BRCA1 protein levels reflect more the dynamics
of cancer cell death, with the CtBP2-overexpressing cells showing the
highest cell death and the greatest loss of BRCA1 expression, while the
knockdown cell lines maintained higher levels of BRCA1 expression.
In conclusion, we propose that CtBP2 is an ovarian cancer onco-
gene that is elevated in the majority of epithelial ovarian cancers and
represses BRCA1 expression. Our data provide strong evidence that
the CtBP2 co-repressor complex plays a significant role in the de-
regulation of BRCA1 function in ovarian carcinomas, which can have
significant clinical relevance. Moreover, as CtBP2 was found over-
expressed in 83% of ovarian epithelial tumors [8,12] and it consistently
downregulates the expression of many cell cycle and DNA repair genes
in addition to BRCA1 for accelerated cell growth, genetic instability,
and tumorigenesis, this CtBP2-dependent epigenetic mechanism ap-
parently plays a central role to affect a large number of clinical cases
of sporadic ovarian carcinoma. Further studies employing ChIP cou-
pled with genome tiling microarrays (ChIP-chip) and sequencing
(ChIP-Seq) are warranted to delineate genome-wide in vivo binding
sites and target genes regulated by CtBP2 complex. The CtBP2 inhibi-
tor MTOB was lethal to ovarian cancer cells overexpressing CtBP2. Fu-
ture studies may determine if the cytotoxic drug MTOB is an effective
targeted therapy for patients with CtBP2-positive ovarian carcinoma.
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Table W1. Primer Sequences Used in the qRT-PCRs.
Gene Forward Primer Reverse Primer
ATAD2 5′-GCGGAGGAAAAGGAGTCGTAA-3′ 5′-AACATCGGCAAGGCTTGCT-3′
ASF1B 5′-TATGTTGGCTCGGCTGAGAGT-3′ 5′-CGTCGGCCTGAAAGACAAA-3′
BRCA1 5′-TGTGAAGGCCCTTTCTTCTG-3′ 5′-TCAAGGAACCTGTCTCCACA-3′
CCL2 5′-TCTCGCCTCCAGCATGAAAGT-3′ 5′-GCATTGATTGCATCTGGCTGA-3′
CCNE2 5′-AAAGCCTCAGGTTTGGAGTGG-3′ 5′-TGTCCCCCTTTTCTGAAGGTG-3′
CENP1 5′-CAAGATGATGCACTGTGCCCT-3′ 5′-GCATTCCCATTTTGGCCTG-3′
CDKN3 5′-CCATCATCATCCAATCGCAG-3′ 5′-TCTCCCAAGTCCTCCATAGCA-3′
DIAPH3 5′-TGCCAAAAGATGTTCGGCAG-3′ 5′-TTAAGCTCCTTGGCGACTGGA-3′
ESCO2 5′-TCATCGACGCTGGTCAGAAAC-3′ 5′-TCCAGAAACCTGTGGTGATGC-3′
FANCD2 5′-AAGCAATGTATGCCGCTCCT-3′ 5′-TTGGAATGCCCACACAGGT-3′
FBXO5 5′-CTGAGGTTGCCAAGACATTGAA-3′ 5′-CAAATCCACAGCCTTCTCGTTT-3′
HIST1H3B 5′-AGACCGATCTTCGCTTCCAGA-3′ 5′-TAGCATGGATGGCGCAAAG-3′
KIF15 5′-TGAGCCCAAGACCTTCACGTT-3′ 5′-CGCTCATGCAAGACTCCACAA-3′
MCM8 5′-TGCCCTGGTACTTGGTGATCA-3′ 5′-TACTTTGCTGCTCCATGGCTT-3′
MND1 5′-GTGATCCGCAAGTTGTGGAAG-3′ 5′-GGCCCAAGATTTTATTGCGA-3′
MNS1 5′-ATGAAGCAGCTGGAACACAGG-3′ 5′-AAATCCTTGCCGCCTTTGC-3′
MYBL2 5′-AGTTTGGACAGCAGGACTGGA-3′ 5′-CCCCTTGACAAGGTCTGGATT-3′
NCAPG2 5′-CTGCACTTTGTTGGATTGCCT-3′ 5′-AAGCTGTGTTGCTCTTGGCCT-3′
PKMYT1 5′-ACAGCAGCGGATGTGTTCAGT-3′ 5′-TCCAGCATCATGACAAGGACA-3′
RAD54L 5′-TCAAAGCCTTTCAAAGTCCCC-3′ 5′-GGCTCATACAGAACCAAGGCA-3′
RFC4 5′-AGCGGAGAGAACAAGAAAGCC-3′ 5′-AGCACTGCAACCACTTCTTCC-3′
SGOL1 5′-GCCAAGGAAAGATGCCTGA-3′ 5′-CCTGCGTTTGCCAATCTCT-3′
SPC24 5′-CCGTGTACGTGGCTCAACTTT-3′ 5′-TCGCTGATGAATTTCCTGGAG-3′
SPC25 5′-TTGAAATCGGAAAGTTGGCG-3′ 5′-CGAAAAGTGCCAGTTCGTCCT-3′
TAF9B 5′-ATAGCAACCCCACAAACGGTG-3′ 5′-TGCAGGAACTGGTTTGACAGG-3′
THBS1 5′-CATCCAAAGCGTCTTCACCAG-3′ 5′-TGGAACCATTCACCACGTTGT-3′
ZWINT 5′-GCCATCAAAATTGGCCTCAC-3′ 5′-GCCATTTGTTTCTTGGCCTG-3′
Cyclophilin A 5′-CTGGACCCAACACAAATGGTT-3′ 5′-CATGCCTTCTTTCACTTTGCC-3′
Figure W1. Expression of CtBP proteins in ovarian cancer cells.
Westernblot analysis to show theexpressionofCtBP1andCtBP2pro-
teins in the MCAS cell lines harboring, respectively, CtBP2-targeting
shRNA constructs or an extra copy of CtBP2 expression construct.
β-Actin was used as a loading control.
Figure W2. Heat map of the 85-gene expression signature in the
control and CtBP2 knockdown MCAS and SKOV3 cell lines.
Table W2. The 85-Gene Signature for CtBP2 Function Identified by Gene Expression Profiling.
Log Ratio ID Symbol Entrez Gene Name Location Type(s)
−0.501 8042195 AHSA2 AHA1, activator of heat shock 90 kDa protein ATPase homolog 2 ( yeast) Unknown Other
0.658 8171823 APOO Apolipoprotein O Unknown Other
0.655 7966315 ARPC3 Actin-related protein 2/3 complex, subunit 3, 21 kDa Cytoplasm Other
0.949 8034772 ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) Nucleus Other
0.831 7940643 ASRGL1 Asparaginase-like 1 Cytoplasm Enzyme
0.879 8152668 ATAD2 ATPase family, AAA domain containing 2 Nucleus Other
0.583 8015769 BRCA1 Breast cancer 1, early onset Nucleus Transcription regulator
0.606 7922095 BRP44 Brain protein 44 Plasma membrane Other
0.618 7972674 C13ORF27 Chromosome 13 open reading frame 27 Unknown Other
0.557 8097435 C4ORF33 Chromosome 4 open reading frame 33 Unknown Other
0.630 8029831 CALM3 Calmodulin 3 ( phosphorylase kinase, delta) Plasma membrane Other
1.300 8006433 CCL2 Chemokine (C-C motif ) ligand 2 Extracellular space Cytokine
0.863 8151871 CCNE2 Cyclin E2 Nucleus Other
1.052 7974404 CDKN3 Cyclin-dependent kinase inhibitor 3 Nucleus Phosphatase
1.274 8168794 CENPI Centromere protein I Nucleus Other
0.683 7985213 CHRNA5 Cholinergic receptor, nicotinic, alpha 5 Plasma membrane Transmembrane receptor
0.609 7917885 CNN3 Calponin 3, acidic Cytoplasm Other
0.527 8174972 DCAF12L1 DDB1 and CUL4-associated factor 12–like 1 Unknown Other
−0.797 7912537 DHRS3 Dehydrogenase/reductase (SDR family) member 3 Cytoplasm Enzyme
1.010 7971866 DIAPH3 Diaphanous homolog 3 (Drosophila) Cytoplasm Enzyme
0.510 8016609 DLX3 Distal-less homeobox 3 Nucleus Transcription regulator
0.603 8128284 EPHA7 EPH receptor A7 Plasma membrane Kinase
−0.761 8096425 FAM190A Family with sequence similarity 190, member A Unknown Other
0.926 8129763 FAM54A Family with sequence similarity 54, member A Unknown Other
0.800 8077731 FANCD2 Fanconi anemia, complementation group D2 Nucleus Other
0.792 8130374 FBXO5 F-box protein 5 Nucleus Enzyme
−0.903 7917530 GBP2 Guanylate-binding protein 2, interferon-inducible Cytoplasm Enzyme
0.745 8040440 GEN1 Gen homolog 1, endonuclease (Drosophila) Unknown Enzyme
0.709 8124397 HIST1H1C Histone cluster 1, H1c Nucleus Other
1.053 8124510 HIST1H2BL Histone cluster 1, H2bl Nucleus Other
0.575 8117330 HIST1H3A Histone cluster 1, H3a Unknown Other
1.368 8124388 HIST1H3B Histone cluster 1, H3b Nucleus Other
0.615 8124531 HIST1H3I Histone cluster 1, H3i Unknown Other
0.519 8124385 HIST1H4B Histone cluster 1, H4b Nucleus Other
0.640 8169984 HPRT1 Hypoxanthine phosphoribosyltransferase 1 Cytoplasm Enzyme
0.927 7991374 IDH2 Isocitrate dehydrogenase 2 (NADP+), mitochondrial Cytoplasm Enzyme
1.395 8043981 IL1R2 Interleukin-1 receptor, type II Plasma membrane Transmembrane receptor
0.532 7916727 ITGB3BP Integrin beta 3 binding protein (beta 3-endonexin) Nucleus Other
0.960 8089372 KIAA1524 KIAA1524 Cytoplasm Other
1.066 8079237 KIF15 Kinesin family member 15 Nucleus Other
1.037 8016147 KIF18B Kinesin family member 18B Unknown Other
0.967 8016139 KIF18B Kinesin family member 18B Unknown Other
−0.653 8158164 LOC389791 Hypothetical LOC389791 Unknown Other
−0.507 8008493 LUC7L3 LUC7-like 3 (S. cerevisiae) Nucleus Other
0.872 7926821 MASTL Microtubule-associated serine/threonine kinase-like Unknown Kinase
0.605 8175177 MBNL3 Muscleblind-like 3 (Drosophila) Nucleus Other
0.763 8060813 MCM8 Minichromosome maintenance complex component 8 Nucleus Enzyme
−1.104 7916984 MIR186 MicroRNA 186 Unknown MicroRNA
1.015 8097857 MND1 Meiotic nuclear divisions 1 homolog (S. cerevisiae) Nucleus Other
0.591 7989146 MNS1 Meiosis-specific nuclear structural 1 Unknown Other
0.785 8041027 MRPL33 Mitochondrial ribosomal protein L33 Unknown Other
1.444 7995825 MT1F Metallothionein 1F Cytoplasm Other
1.406 8062766 MYBL2 V-myb myeloblastosis viral oncogene homolog (avian)–like 2 Nucleus Transcription regulator
0.711 8175924 NAA10 N (alpha)-acetyltransferase 10, NatA catalytic subunit Nucleus Enzyme
0.948 8144153 NCAPG2 Non-SMC condensin II complex, subunit G2 Nucleus Other
0.623 8031097 NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9 kDa Cytoplasm Enzyme
0.714 8098423 NEIL3 Nei endonuclease VIII-like 3 (E. coli) Nucleus Enzyme
0.657 8177130 NHEDC1 Na+/H+ exchanger domain containing 1 Unknown Other
−0.598 8069553 NRIP1 Nuclear receptor interacting protein 1 Nucleus Transcription regulator
−0.670 8047738 NRP2 Neuropilin 2 Plasma membrane Kinase
0.701 7923753 NUAK2 NUAK family, SNF1-like kinase, 2 Unknown Kinase
0.535 7995354 ORC6L Origin recognition complex, subunit 6 like ( yeast) Nucleus Other
−0.532 8059996 PER2 Period homolog 2 (Drosophila) Nucleus Other
0.895 7998886 PKMYT1 Protein kinase, membrane-associated tyrosine/threonine 1 Cytoplasm Kinase
0.585 8169473 PLS3 Plastin 3 Cytoplasm Other
0.770 7964271 PRIM1 Primase, DNA, polypeptide 1 (49 kDa) Nucleus Enzyme
0.698 8169240 PRPS1 Phosphoribosyl pyrophosphate synthetase 1 Unknown Kinase
0.514 8135250 PSMC2 Proteasome ( prosome, macropain) 26S subunit, ATPase, 2 Nucleus Peptidase
0.665 7901192 RAD54L RAD54-like (S. cerevisiae) Nucleus Enzyme
0.627 8092640 RFC4 Replication factor C (activator 1) 4, 37 kDa Nucleus Other
−0.814 8112865 SERINC5 Serine incorporator 5 Plasma membrane Transporter
1.154 8085754 SGOL1 Shugoshin-like 1 (S. pombe) Nucleus Other
1.011 8001133 SHCBP1 SHC SH2-domain binding protein 1 Unknown Other
Table W3. Key Functional Networks of the 85-Gene Expression Signature Identified by GeneGo MetaCore (Top) and Ingenuity Pathway Analysis (Bottom) Programs.
GO Process P Value
Cell cycle 4.03105E − 12
Cell cycle process 8.58197E − 12
Cell cycle phase 1.03412E − 10
M phase 1.55910E − 10
DNA packaging 1.84488E − 10
DNA conformation change 1.01005E − 09
Protein-DNA complex assembly 1.06819E − 08
Protein-DNA complex subunit organization 1.81620E − 08
Nucleosome assembly 8.91502E − 08
Chromatin assembly 1.16916E − 07
ID Score Focus Molecules Top Functions
1 35 17 Cell cycle, cancer, decreased levels of albumin
2 28 14 Cell cycle, cellular assembly and organization, DNA replication, recombination, and repair
3 25 13 Cellular development, cell death, cell-to-cell signaling and interaction
4 22 12 Cell cycle, cancer, hematological disease
5 14 8 Digestive system development and function, lipid metabolism, molecular transport
Table W2. (continued )
Log Ratio ID Symbol Entrez Gene Name Location Type(s)
−0.569 8130580 SNORA29 Small nucleolar RNA, H/ACA box 29 Unknown Other
−0.530 8114468 SNORD63 Small nucleolar RNA, C/D box 63 Unknown Other
0.743 8034122 SPC24 SPC24, NDC80 kinetochore complex component, homolog (S. cerevisiae) Unknown Other
0.931 8056572 SPC25 SPC25, NDC80 kinetochore complex component, homolog (S. cerevisiae) Unknown Other
1.058 8173732 TAF9B TAF9B RNA Pol II, TATA box binding protein (TBP)–associated factor, 31 kDa Nucleus Transcription regulator
1.058 8176263 TAF9B TAF9B RNA Pol II, TATA box binding protein (TBP)–associated factor, 31 kDa Nucleus Transcription regulator
−0.508 7961281 TAS2R50 Taste receptor, type 2, member 50 Unknown Other
1.660 7982597 THBS1 Thrombospondin 1 Extracellular space Other
0.873 8177983 TNF Tumor necrosis factor Extracellular space Cytokine
0.873 8118142 TNF Tumor necrosis factor Extracellular space Cytokine
0.873 8179263 TNF Tumor necrosis factor Extracellular space Cytokine
−0.520 7958960 TPCN1 Two pore segment channel 1 Plasma membrane ion channel
−0.724 7897172 TPRG1L Tumor protein p63 regulated 1-like Unknown Other
0.507 7976336 UBR7 Ubiquitin protein ligase E3 component n-recognin 7 ( putative) Unknown Enzyme
−0.576 8003180 ZDHHC7 Zinc finger, DHHC-type containing 7 Cytoplasm Enzyme
0.827 7933707 ZWINT ZW10 interactor Nucleus Other
Figure W3. qRT-PCRs to verify the differential expression of identified genes of the BRCA1 pathway in the control and CtBP2 knock-
down cell lines. The expression in control cell lines is defined as 1. Significance of differences was determined using two-tailed t test.
*P < .01; **P < .05.
Figure W4. Estradiol treatment did not result in changes of BRCA1
level in ovarian cancer cells. Ovarian cancer cell lines MCAS (lanes 1
and 2), OVCA432 (lanes 3 and 4), and RMUGL (lanes 5 and 6) were
treated with 100 nM estradiol for 30 minutes before harvesting for
lysates and Western blot analysis. MCAS cancer cells with CtBP2
knockdown (lane 7) was used as reference. The estrogen receptor (ER)
signal in lanes 3 and 4was observed only after a long (1 hour) exposure.
Figure W5. Sensitivity of ovarian cancer cell lines with changes of CtBP2 expression to CtBP2 inhibitor MTOB. (A) Measurement of cell
viability using the xCELLigence System (Roche Applied Science). Cell viability kinetics are presented as linear slopes of the cell indices.
(B) Western blot analysis of cell lysates for BRCA1 expression after MTOB treatment.
